Anticancer Therapy

Increased awareness of the quality-of-life harm and financial burden associated with continued cancer treatment at the end of a patient’s life has led professional societies to promote reduced systemic anticancer therapy at this stage.

The FDA granted priority review to four anticancer therapies or combinations for the treatment of various subtypes of lung cancer.